ReviewJournal of gastroenterology and hepatology2022

Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.

Bo Hyun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.